Novogene provides genomic services and solutions, leveraging next-generation sequencing (NGS) and bioinformatics expertise.

Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus, a next-generation sequencing based companion diagnostic assay for PARP inhibitor therapies; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. Novogene Co., Ltd. has a strategic partnership with Hummingbird Bioscience Pte. Ltd. to support the development of investigational drug candidate HMBD-001, an anti-HER3 antibody to be evaluated for treatment of various tumor types, including NRG1-fusion driven cancers. The company was founded in 2011 and is headquartered in Beijing, China.

6883

COM:NOVOGENE

Novogene

Last Close

12.83

31/10 07:00

Market Cap

4.43B

Beta: -

Volume Today

5.94M

Avg: -

locale

market

industry

website

ipo date

competitor of

Metrics